Applied Biosciences Corp. (APPB)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Applied Biosciences Corp. (APPB) with AI Score 39/100 (Weak). Applied Biosciences Corp. develops and commercializes synthetic cannabinoid therapeutics and THC-free CBD products. The company also provides testing and analytics services. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Applied Biosciences Corp. (APPB) Healthcare & Pipeline Overview
Applied Biosciences Corp. focuses on synthetic cannabinoid therapeutics and THC-free CBD products, targeting the endocannabinoid system. Operating in the specialty and generic drug manufacturing sector, the company provides testing and analytics services, distinguishing itself through a vertically integrated approach from development to consumer products, despite its current financial challenges.
Investment Thesis
Applied Biosciences Corp. presents a high-risk, high-reward investment opportunity within the cannabinoid therapeutics and consumer CBD market. The company's focus on synthetic cannabinoids offers potential for novel treatments targeting the endocannabinoid system. However, its negative profit margin of -865.3% and gross margin of -358.5% indicate significant financial challenges. Future growth hinges on successful drug development, regulatory approvals, and market acceptance of its CBD products. The company's high beta of 732.83 suggests extreme volatility, making it suitable only for investors with a high-risk tolerance. Investment is contingent on the company securing additional funding and demonstrating progress in its clinical programs.
Based on FMP financials and quantitative analysis
Key Highlights
- Focus on synthetic cannabinoid therapeutics targeting the endocannabinoid system.
- Offers a range of THC-free CBD products for consumer use.
- Provides testing and analytics services to customers in the cannabinoid market.
- Incorporated in 2014, indicating a relatively young company in the biopharmaceutical sector.
- Based in Beverly Hills, California, a hub for the health and wellness industry.
Competitors & Peers
Strengths
- Focus on synthetic cannabinoids offers potential for novel therapeutics.
- Offers a range of THC-free CBD products for consumer use.
- Provides testing and analytics services, creating additional revenue streams.
- Vertically integrated business model allows for greater control over the supply chain.
Weaknesses
- Negative profit and gross margins indicate financial instability.
- High beta suggests extreme stock price volatility.
- Limited information available regarding specific products in development.
- Small number of employees (25) may limit operational capacity.
Catalysts
- Upcoming: Potential regulatory approvals for synthetic cannabinoid therapeutics.
- Ongoing: Expansion of the company's THC-free CBD product line.
- Ongoing: Increasing consumer awareness and acceptance of CBD products.
Risks
- Potential: Stringent regulatory requirements for cannabinoid-based products.
- Ongoing: Competition from larger, more established companies.
- Potential: Adverse effects or safety concerns associated with cannabinoid products.
- Ongoing: The company's financial instability, as indicated by negative profit and gross margins.
- Potential: Dependence on key personnel and the ability to attract and retain talent.
Growth Opportunities
- Expansion of Synthetic Cannabinoid Therapeutics: Applied Biosciences has the opportunity to develop and commercialize novel synthetic cannabinoid therapeutics targeting specific diseases. The global pharmaceutical market is multi-billion dollar, offering significant revenue potential for successful drug candidates. This opportunity depends on positive clinical trial results and regulatory approvals, with a timeline of several years for drug development and commercialization.
- Growth in the CBD Consumer Market: The market for CBD consumer products is experiencing rapid growth, driven by increasing consumer awareness and acceptance. Applied Biosciences can capitalize on this trend by expanding its range of THC-free CBD products and distribution channels. The global CBD market is projected to reach billions of dollars by 2030, presenting a substantial growth opportunity. Success depends on effective marketing, product innovation, and compliance with evolving regulations.
- Strategic Partnerships and Collaborations: Applied Biosciences can accelerate its growth by forming strategic partnerships with other companies in the pharmaceutical, biotechnology, and consumer product sectors. Collaborations can provide access to new technologies, markets, and funding sources. This strategy can reduce risk and accelerate the development and commercialization of its products. The timeline for realizing this opportunity depends on identifying suitable partners and negotiating mutually beneficial agreements.
- Development of Novel Drug Delivery Systems: Applied Biosciences can enhance the efficacy and patient experience of its cannabinoid therapeutics by developing novel drug delivery systems. This can include formulations for improved bioavailability, targeted delivery to specific tissues, and convenient routes of administration. The market for advanced drug delivery technologies is growing, driven by the demand for more effective and patient-friendly therapies. Success depends on innovation in formulation science and engineering.
- Expansion of Testing and Analytics Services: Applied Biosciences can leverage its testing and analytics capabilities to serve the growing demand for quality control and regulatory compliance in the cannabinoid industry. This includes providing testing services for other companies' products, as well as developing analytical tools for research and development. The market for cannabis testing services is expanding rapidly, driven by increasing regulation and consumer demand for product safety and transparency. Success depends on maintaining high standards of accuracy and reliability.
Opportunities
- Expanding the range of synthetic cannabinoid therapeutics through research and development.
- Increasing market share in the growing CBD consumer market.
- Forming strategic partnerships to expand reach and resources.
- Capitalizing on the increasing demand for cannabinoid testing and analytics services.
Threats
- Stringent regulatory requirements for cannabinoid-based products.
- Competition from larger, more established pharmaceutical and consumer product companies.
- Changing consumer preferences and market trends.
- Potential for adverse effects or safety concerns associated with cannabinoid products.
Competitive Advantages
- Proprietary synthetic cannabinoid formulations.
- Vertically integrated business model, encompassing drug development, consumer products, and analytical services.
- Expertise in targeting the endocannabinoid system.
- Established brand recognition in the THC-free CBD market.
About APPB
Applied Biosciences Corp., incorporated in 2014 and based in Beverly Hills, California, is a biopharmaceutical company focused on the development and commercialization of synthetic cannabinoid therapeutics. These therapeutics target the endocannabinoid system, aiming to treat a variety of diseases across multiple therapeutic areas. In addition to its pharmaceutical development efforts, Applied Biosciences delivers consumer and OTC THC-free CBD products designed to promote overall health and wellbeing. The company also offers testing and analytics capabilities to its customers, providing a comprehensive suite of services within the cannabinoid market. Since its founding, Applied Biosciences has positioned itself as an innovator in the cannabinoid space, seeking to leverage the therapeutic potential of both synthetic cannabinoids and CBD. The company's strategy involves a vertically integrated approach, encompassing drug development, consumer product formulation, and analytical services. This allows Applied Biosciences to capture value across the entire cannabinoid value chain, from research and development to direct-to-consumer sales. Despite its innovative approach, the company faces challenges common to early-stage biopharmaceutical companies, including the need for significant capital investment and the complexities of regulatory approval processes.
What They Do
- Develops synthetic cannabinoid therapeutics.
- Commercializes synthetic cannabinoid therapeutics.
- Creates THC-free CBD products for consumer use.
- Sells THC-free CBD products for consumer use.
- Provides testing services for cannabinoid products.
- Provides analytics services for cannabinoid products.
Business Model
- Develops and patents synthetic cannabinoid formulations.
- Manufactures and distributes THC-free CBD products directly to consumers and through retail channels.
- Generates revenue through the sale of CBD products.
- Offers testing and analytics services to other companies in the cannabinoid industry.
Industry Context
Applied Biosciences Corp. operates in the rapidly evolving cannabinoid market, which includes both pharmaceutical and consumer segments. The industry is characterized by increasing research into the therapeutic potential of cannabinoids, growing consumer demand for CBD products, and evolving regulatory landscapes. Competition includes established pharmaceutical companies, specialized cannabinoid biotechs, and numerous CBD consumer brands. Applied Biosciences aims to differentiate itself through its focus on synthetic cannabinoids and its integrated approach, but it faces challenges from larger, better-funded competitors and the uncertainties of regulatory approval.
Key Customers
- Consumers seeking THC-free CBD products for health and wellness.
- Patients who may benefit from synthetic cannabinoid therapeutics.
- Other companies in the cannabinoid industry requiring testing and analytics services.
Financials
Chart & Info
Applied Biosciences Corp. (APPB) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Dec 3, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for APPB.
Price Targets
Wall Street price target analysis for APPB.
MoonshotScore
What does this score mean?
The MoonshotScore rates APPB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Christopher Michael Bridges
CEO
Christopher Michael Bridges serves as the CEO of Applied Biosciences Corp. His background includes experience in managing teams and leading companies, as evidenced by his current role overseeing 25 employees. Additional details regarding his specific educational background, prior roles, and industry experience are not available in the provided data. Further research would be needed to provide a more comprehensive profile.
Track Record: Due to limited information, Christopher Michael Bridges' specific achievements and strategic decisions at Applied Biosciences Corp. cannot be fully assessed. The company's current financial state, with negative profit and gross margins, suggests ongoing challenges. Further information is needed to evaluate his track record in driving growth and profitability.
APPB OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Applied Biosciences Corp. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial reporting and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, bankrupt entities, or companies with questionable operations, resulting in higher risk for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in Applied Biosciences Corp.
- The OTC Other tier designation indicates a higher risk of fraud or mismanagement.
- Low trading volume and wide bid-ask spreads can result in significant losses.
- The company's financial instability, as indicated by negative profit and gross margins, poses a significant risk.
- The lack of analyst coverage and institutional interest increases the risk for retail investors.
- Verify the company's registration and legal standing.
- Obtain and review the company's financial statements, if available.
- Assess the company's management team and their track record.
- Research the company's products and services and their market potential.
- Evaluate the company's competitive landscape and its ability to compete.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor before investing.
- The company was incorporated in 2014, indicating some operating history.
- The company has a CEO and a team of 25 employees, suggesting some level of operational activity.
- The company has a website and provides information about its products and services.
What Investors Ask About Applied Biosciences Corp. (APPB)
What does Applied Biosciences Corp. do?
Applied Biosciences Corp. is a biopharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics that target the endocannabinoid system. The company also delivers consumer and OTC THC-free CBD products that promote overall health and wellbeing. In addition, Applied Biosciences provides testing and analytics capabilities to its customers. The company aims to capitalize on the growing interest in cannabinoid-based products and therapies, addressing both the pharmaceutical and consumer markets.
What do analysts say about APPB stock?
There is no available analyst coverage for Applied Biosciences Corp. (APPB). The company's OTC listing and limited financial information may deter analyst coverage. Investors should conduct their own thorough research and due diligence before investing in APPB, considering the lack of external analysis and the inherent risks associated with OTC stocks. Key valuation metrics such as P/E ratio are currently not meaningful due to negative earnings.
What are the main risks for APPB?
Applied Biosciences Corp. faces several significant risks. The company's negative profit and gross margins indicate financial instability and raise concerns about its ability to sustain operations. As an OTC-listed company with limited disclosure, APPB is subject to higher regulatory and operational risks. Competition from larger, more established companies in the cannabinoid market poses a threat to APPB's market share and growth prospects. Stringent regulatory requirements for cannabinoid-based products could delay or prevent the commercialization of its products.
What are the key factors to evaluate for APPB?
Applied Biosciences Corp. (APPB) currently holds an AI score of 39/100, indicating low score. Key strength: Focus on synthetic cannabinoids offers potential for novel therapeutics.. Primary risk to monitor: Potential: Stringent regulatory requirements for cannabinoid-based products.. This is not financial advice.
How frequently does APPB data refresh on this page?
APPB prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven APPB's recent stock price performance?
Recent price movement in Applied Biosciences Corp. (APPB) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on synthetic cannabinoids offers potential for novel therapeutics.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider APPB overvalued or undervalued right now?
Determining whether Applied Biosciences Corp. (APPB) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying APPB?
Before investing in Applied Biosciences Corp. (APPB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available for Applied Biosciences Corp.
- OTC market carries higher risks than major exchanges.
- AI analysis pending for APPB, further insights may be available in the future.